Zika Breaking News

As a frequent airplane traveler who is concerned about catching the flu in crowded cabins with recycled air, I am thrilled by recent research on CR9114. This nasal spray delivers influenza-specific monoclonal antibodies.

This innovative product, if approved, could be ideal for high-exposure situations, such as flying during flu season, especially for travelers.

While modern commercial airplanes have high-efficiency ventilation systems that recirculate cabin air through HEPA filters, they don't remove all viruses. If an infected passenger is on board—especially one who is coughing or sneezing—flu virus transmission can still occur.

Published on February 4, 2026, in Science Translational Medicine, the study, led by researchers from Harvard in collaboration with Leyden Laboratories, demonstrates that the intranasal delivery of the broad-spectrum hemagglutinin antibody CR9114 is both safe and feasible.

In two Phase 1 trials involving healthy volunteers, repeated dosing (twice daily, given the approximately 3-hour nasal half-life) achieved sustained high antibody levels in the nose.

These recovered antibodies retained strong neutralizing activity against both influenza A and B viruses.

Importantly, this nasal spray is not a replacement for seasonal influenza vaccines but rather may offer a rapid, short-term immunoprophylactic option. By delivering high local antibody concentrations directly at the virus's entry point with small doses, CR9114 has shown early promise.

Previous preclinical tests on mice and macaques confirmed its safety and effectiveness against influenza challenge.

These findings lay the groundwork for future efficacy trials and provide proof of concept that intranasal antibodies can elicit efficacious passive immunity against influenza viruses.

For someone who dreads having post-flight sniffles turn into illness, this nasal spray could become an essential item to carry on board before flying.

The Public Health Agency of Canada (PHAC) recently aligned its travel health guidance with that of the U.S. Centers for Disease Control and Prevention (CDC), issuing Level 2 travel notices for Bolivia, Cuba, Seychelles, Sri Lanka, and Suriname due to increased chikungunya virus activity.

As of February 19, 2026, these Level 2 advisories, which call for enhanced precautions, address the higher-than-expected transmission rates of the mosquito-borne illness in these destinations.

These advisories follow an epidemiological alert issued by the Pan American Health Organization (PAHO) on February 10, 2026, which warned of a sustained increase in chikungunya cases across various parts of the Americas since late 2025 and into early 2026.

The alert highlights the re-emergence of local transmission in areas that had been free of the virus for several years, including regions of the Guiana Shield and parts of Florida.

Chikungunya, primarily spread by infected mosquitoes, causes symptoms such as sudden fever, severe joint pain, muscle aches, headaches, nausea, fatigue, and rashes. While rarely fatal, the disease can cause prolonged joint discomfort in some individuals.

In December 2013, the virus was detected for the first time in the Americas Region.

According to PAHO data and related reports, by early 2026 (specifically epidemiological week 4, around late January to early February), 7,150 chikungunya cases had been reported regionally, including 2,351 confirmed cases and 1 death.

Cuba reported a significant number of suspected cases early in the year, with updates indicating that 1,457 were suspected as of late January.

The PHAC and the CDC recommend that travelers to these countries take necessary precautions, such as avoiding mosquito bites. They note that vaccination against chikungunya is available at travel clinics as of February 2026.

The Pan American Health Organization (PAHO) recently announced it has partnered with the Ministry of Health, Wellness, and the Environment of Saint Vincent and the Grenadines to promote the rollout of the human papillomavirus (HPV) vaccine for school-aged children.

On February 11, 2026, PAHO stated that HPV vaccination is a crucial component of cervical cancer prevention, as persistent infections with high-risk HPV types account for the majority of cervical cancer cases throughout the Caribbean Islands.

This collaboration is particularly important in Saint Vincent and the Grenadines, where cervical cancer poses a significant public health challenge.

Recent data revealed that 17 women were diagnosed with cervical cancer in 2024, marking an 88.9% increase from 2023. An additional 17 new cases were recorded in the first nine months of 2025.

From 2020 to 2024, a total of 44 women succumbed to this vaccine-preventable disease.

In 2023, cervical cancer accounted for 12.7% of all cancers among women in Saint Vincent.

The situation is similarly alarming across the Caribbean region, including Cuba and Puerto Rico, which have one of the highest rates of cervical HPV infection globally, at approximately 16% among women, ranking second only to sub-Saharan Africa.

Every year, more than 78,000 women in the Americas are diagnosed with cervical cancer, leading to over 40,000 deaths, 83% of which occur in Latin America and the Caribbean.

Dr. Amalia Del Riego, PAHO/WHO Representative for Barbados and the Eastern Caribbean Countries, welcomed the strong community response to this initiative. "We congratulate the Ministry of Health for advancing the elimination strategy by actively engaging communities," she stated.

"This partnership builds on recent milestones in the country, including the introduction of HPV DNA testing for screening (launched in September 2025) and expanded access to diagnostic and treatment services."

These actions, from vaccination to screening and treatment, represent a holistic approach to eliminating cervical cancer, in line with PAHO and WHO regional and global goals for 2026.

A clinical-stage biotechnology company recently announced that the first participants have been dosed in the company's Phase 1A clinical trial evaluating Centi-Flu 01, a pan-influenza universal flu vaccine.

According to Centivax, the Phase 1A represents a key milestone toward a new kind of flu vaccine designed to provide broader, more reliable protection than standard seasonal vaccines, protecting against currently circulating strains, future strains, and pandemic strains.

The first data from this studyis expected within the year.

Unlike conventional seasonal influenza vaccines, which must be reformulated annually to attempt to match predicted circulating strains, Centi-Flu 01 is designed to focus both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distance subtypes.

This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza.

Sawsan Youssef, PhD, founder and Chief Science Officer of Centivax, stated in a press release on February 12, 2026, "A universal influenza vaccine allows us to be proactive—moving from annual guesswork to predictable, durable response."

In addition to safety, the study will evaluate efficacy based on established correlates of protection, using the gold-standard hemagglutination inhibition (HAI) assay against a panel of more than twenty flu strains—including currently circulating strains, historical mismatch strains, seasonal guidance strains, and pandemic strains—in a direct head-to-head comparison with existing standard-of-care flu vaccines.

Because the HAI assay is the same correlate-of-protection used to license seasonal flu vaccines, positive data will provide a clear benchmark demonstrating the candidate's ability to deliver broad protection with a single vaccine.

This type of innovative flu shot is essential because current vaccines are suboptimal at preventing virus transmission.

The 2024-2025 seasonal flu vaccine (trivalent formulation provided moderate protection in the United States, according to interim estimates from the U.S. CDC. Seasonal influenza effectiveness estimates among children and adolescents was 32%, 59%, and 60% in outpatient settings.

Health authorities in French Guiana, an overseas department of France located on the northeast coast of South America, have confirmed the re-emergence of local Chikungunya transmission for the first time since 2015.

The initial case was identified in a resident of Kourou by the French Guiana Regional Health Agency through RT-PCR testing on January 27, 2026.

This case was classified as locally acquired, meaning the patient contracted the virus from a mosquito bite in French Guiana, without having recently traveled to affected areas like Brazil. Subsequent investigations have revealed three additional confirmed cases.

The virus strain detected in these cases is genetically similar to the one currently circulating across parts of the Americas, according to the Pan American Health Organization (PAHO), which issued an epidemiological alert on February 10, 2026.

The alert noted the resumption of transmission in the Guiana Shield region—including Guyana, French Guiana, and Suriname.

The PAHO has urged heightened preparedness across the Americas amid rising chikungunya activity in several countries since late 2025. The reappearance of local transmission in areas long free of the Chikungunya virus underscores the risk posed by ongoing viral activity in neighboring countries and the potential for imported cases to spark outbreaks

This resurgence aligns with broader regional trends in 2025.

PAHO data indicate sustained increases in chikungunya cases in parts of South America and the Caribbean since late 2025, even as overall regional numbers have declined compared to the peaks in 2024.

The situation is under close monitoring by French health authorities and international partners, with no reports of severe complications or large-scale outbreaks at this stage.

However, in central South America, the U.S. Centers for Disease Control and Prevention (CDC) has identified parts of Bolivia as experiencing an ongoing chikungunya outbreak.

Currently, the CDC says there is no specific antiviral treatment; management focuses on symptom relief, and prevention relies on mosquito control and personal protective measures such as repellents, long clothing, and eliminating breeding sites.

Travelers to the region are encouraged by the PAHO and other agencies to consult health guidelines and consider protective measures, such as vaccination, before visiting the Guiana Shield region as of February 16, 2026.

The U.S. Centers for Disease Control and Prevention (CDC) has identified parts of Bolivia as health risk destinations in South America due to an ongoing outbreak of chikungunya fever, a mosquito-borne viral illness.

As of mid-February 2026, there have been 1,534 confirmed or suspected cases reported nationwide.

A Travel Health Notice issued on February 11, 2026, classifies the situation as a Level 2 – Practice Enhanced Precautions, specifically highlighting outbreaks in the departments of Santa Cruz (eastern Bolivia) and Cochabamba (central Bolivia), while smaller numbers have been noted in Tarija (14), Beni (10), and Chuquisaca (7).

The CDC writes that Chikungunya, primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes, causes symptoms such as high fever, severe joint pain, muscle pain, headache, nausea, fatigue, and rash. While most individuals recover within a week, some may experience persistent joint pain for months or even years. Severe complications are rare but can occur, especially in vulnerable groups such as older adults, infants, and those with underlying health conditions.

There is no specific antiviral treatment available, but the CDC recommends a vaccine for travelers visiting outbreak areas. 

In its notice, the CDC urges travelers to Bolivia, especially those visiting affected regions, to take proactive measures to avoid mosquito bites.

The outbreak in Bolivia is part of a broader regional trend in the Americas.

The Pan American Health Organization (PAHO) noted sustained increases in chikungunya cases since late 2025, with a re-emergence in areas such as the Guiana Shield (Guyana, French Guiana, Suriname) after nearly a decade without reports.

In 2025, the Americas reported 313,132 cases (113,926 confirmed, including 170 deaths) across 18 countries and one territory, though overall regional numbers declined compared to 2024.

The CDC and PAHO say travelers to outbreak areas should consult travel health providers about vaccination options before their trips and monitor updates, as conditions can evolve rapidly due to changes in mosquito populations and environmental factors.